Shattuck Labs, Inc. (STTK) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
500 West 5th Street
Austin, TX 78703
United States of America (the)
Phone
512 900 4690
Website
Sector
Healthcare
Industry
Biotechnology
Employees
44
First IPO Date
October 09, 2020
| Name | Title | Pay | Year Born |
| Taylor H. Schreiber | Co-Founder, Chief Executive Officer & Director | 876,232 | 1980 |
| Casi DeYoung | Chief Business Officer | 523,482 | 1971 |
| Abhinav A. Shukla | Chief Technical Officer | 567,398 | 1973 |
| Andrew R. Neill | Chief Financial Officer | 678,207 | 1986 |
| Arundathy Nirmalini Pandite | Chief Medical Officer | 734,899 | 1959 |
| Brad Huckabee | Vice President of Accounting & SEC reporting | 0 | N/A |
| Suresh de Silva | Chief Scientific Officer | 0 | N/A |
| Kelli Collin | Senior Vice President of Quality | 0 | N/A |
| Stephen Stout | General Counsel, Corporate Secretary and Chief Ethics & Compliance Officer | 0 | 1975 |
| Thomas Lampkin | Senior Vice President of Regulatory Affairs | 0 | N/A |
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.